TGFB2 and BCL2L11 methylation in male laryngeal cancer patients

被引:3
|
作者
Shen, Zhisen [1 ]
Chen, Xiaoying [2 ]
Li, Qun [1 ,2 ]
Ye, Huadan [2 ]
Li, Jinyun [2 ]
Zhou, Chongchang [1 ,2 ]
Duan, Shiwei [2 ]
机构
[1] Ningbo Univ, Dept Otorhinolaryngol, Lihuili Hosp, 57 Xingning Rd, Ningbo 315040, Zhejiang, Peoples R China
[2] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, 818 Fenghua Rd, Ningbo 315211, Zhejiang, Peoples R China
关键词
laryngeal cancer; transforming growth factor 2; B cell lymphoma 2-like 11; DNA methylation; male; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-BETA; NECK-CANCER; PROMOTER METHYLATION; PROSTATE-CANCER; GENE; HEAD; HYPERMETHYLATION; RISK;
D O I
10.3892/ol.2016.5018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DNA methylation is a major regulatory mechanism of gene expression. The aim of the present study was to test the association of transforming growth factor 2 (TGFB2) and B cell lymphoma 2-like 11 (BCL2L11) gene methylation with the risk of laryngeal squamous cell carcinoma (LSCC). Using bisulfite pyrosequencing technology, DNA methylation levels of TGFB2 promoter and BCL2L11 gene-body CpG cytosines were measured in 90 LSCC tissues and 90 adjacent normal tissues. Analysis of variance and paired sample t-test were used to determine the association of gene methylation and the risk of LSCC. Our results revealed that there were no differences in TGFB2 and BCL2L11 methylation levels between the LSCC tissues and the paired normal tissues (P>0.05). Further breakdown analyses demonstrated that the association results of the two gene methylation levels and LSCC remained unchanged with the age, smoking history, histological differentiation or clinical stage of the LSCC patients (all adjusted P>0.05). In conclusion, there is no association of TGFB2 promoter and BCL2L11 gene-body methylation with the risk of LSCC in males.
引用
收藏
页码:2999 / 3003
页数:5
相关论文
共 50 条
  • [1] BCL2L11 Is Associated With Kawasaki Disease in Intravenous Immunoglobulin Responder Patients
    Kwon, Young-Chang
    Kim, Jae-Jung
    Yun, Sin Weon
    Yu, Jeong Jin
    Yoon, Kyung Lim
    Lee, Kyung-Yil
    Kil, Hong-Ryang
    Kim, Gi Beom
    Han, Myung-Ki
    Song, Min Seob
    Lee, Hyoung Doo
    Ha, Kee Soo
    Sohn, Sejung
    Hong, Young Mi
    Jang, Gi Young
    Lee, Jong-Keuk
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (02):
  • [2] BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer
    Rose, Madison M.
    Espinoza, Veronica L.
    Hoff, Katelyn J.
    Pike, Laura A.
    Sharma, Vibha
    Hofmann, Marie-Claude
    Tan, Aik Choon
    Pozdeyev, Nikita
    Schweppe, Rebecca E.
    CANCERS, 2023, 15 (02)
  • [3] Corneal thinning and cornea guttata in patients with mutations in TGFB2
    Eghrari, Allen O.
    Rasooly, Marjohn M.
    Fliotsos, Michael J.
    Kinard, Jessica
    Odozor, Obinna
    Cunningham, Denise
    Bishop, Rachel J.
    Guerrerio, Anthony L.
    Frischmeyer-Guerrerio, Pamela A.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2020, 55 (04): : 336 - 341
  • [4] BCL2L11/BIM A novel molecular link between autophagy and apoptosis
    Luo, Shouqing
    Rubinsztein, David C.
    AUTOPHAGY, 2013, 9 (01) : 104 - 105
  • [5] Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer
    Haiyang Zhang
    Jingjing Duan
    Yanjun Qu
    Ting Deng
    Rui Liu
    Le Zhang
    Ming Bai
    Jialu Li
    Tao Ning
    Shaohua Ge
    Xia Wang
    Zhenzhen Wang
    Qian Fan
    Hongli Li
    Guoguang Ying
    Dingzhi Huang
    Yi Ba
    Protein & Cell, 2016, 7 (02) : 141 - 151
  • [6] Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer
    Zhang, Haiyang
    Duan, Jingjing
    Qu, Yanjun
    Deng, Ting
    Liu, Rui
    Zhang, Le
    Bai, Ming
    Li, Jialu
    Ning, Tao
    Ge, Shaohua
    Wang, Xia
    Wang, Zhenzhen
    Fan, Qian
    Li, Hongli
    Ying, Guoguang
    Huang, Dingzhi
    Ba, Yi
    PROTEIN & CELL, 2016, 7 (02) : 141 - 151
  • [7] Identification of a candidate alternative promoter region of the human Bcl2L11 (Bim) gene
    Gaviraghi, Margherita
    Caricasole, Andrea
    Costanzo, Chiara
    Diamanti, Daniela
    Dandrea, Mario
    Donadelli, Massimo
    Scarpa, Aldo
    Palmieri, Marta
    BMC MOLECULAR BIOLOGY, 2008, 9
  • [8] Expression Levels of MicroRNA-300/BCL2L11 in Papillary Thyroid Cancer and Their Clinical Diagnostic Values
    Shen, Yi
    Li, Xiaoen
    Xie, Rongli
    Chen, Yupan
    Hu, Xun
    Liu, Yaping
    Ma, He
    EUROPEAN SURGICAL RESEARCH, 2023, 64 (03) : 342 - 351
  • [9] Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
    Li, Xuanzong
    Zhang, Dai
    Li, Butuo
    Zou, Bing
    Wang, Shijiang
    Fan, Bingjie
    Li, Wanlong
    Yu, Jinming
    Wang, Linlin
    LUNG CANCER, 2021, 151 : 39 - 43
  • [10] The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients
    Katagiri, Seiichiro
    Umezu, Tomohiro
    Ohyashiki, Junko H.
    Ohyashiki, Kazuma
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (02) : 269 - 272